@article {27251,
	title = {Accelerated DNA methylation age and the use of antihypertensive medication among older adults},
	journal = {Aging (Albany NY)},
	volume = {10},
	number = {11},
	year = {2018},
	note = {Gao, Xu Colicino, Elena Shen, Jincheng Just, Allan C Nwanaji-Enwerem, Jamaji C Wang, Cuicui Coull, Brent Lin, Xihong Vokonas, Pantel Zheng, Yinan Hou, Lifang Schwartz, Joel Baccarelli, Andrea A eng R01 ES025225/ES/NIEHS NIH HHS/ R01 ES021733/ES/NIEHS NIH HHS/ P30 ES023515/ES/NIEHS NIH HHS/ R01 ES027747/ES/NIEHS NIH HHS/ F31 AG056124/AG/NIA NIH HHS/ R00 ES023450/ES/NIEHS NIH HHS/ P30 ES009089/ES/NIEHS NIH HHS/ Research Support, N.I.H., Extramural Research Support, U.S. Gov\&$\#$039;t, Non-P.H.S. Aging (Albany NY). 2018 Nov 10;10(11):3210-3228. doi: 10.18632/aging.101626.},
	pages = {3210-3228},
	type = {Journal Article},
	abstract = {The discrepancy of DNA methylation age (DNAmAge) with chronological age (termed as age acceleration, AA) has been identified to be associated with many aging-related health outcomes including hypertension. Since taking antihypertensive medication (AHM) could prevent aging-related diseases caused by hypertension, we hypothesized that using AHM could also reduce the AA. We examined this hypothesis among 546 males aged 55-85 years by exploring the associations of AHM use with AA and its change rate (DeltaAA) in two visits with a median follow-up of 3.86 years. Horvath DNAmAge was derived from DNA methylation profiles measured by Illumina HumanMethylation450 BeadChip and information on AHM use was collected by physician interview. A general decreasing pattern of AA was observed between the two visits. After the fully adjusting for potential covariates including hypertension, any AHM use showed a cross-sectional significant association with higher AA at each visit, as well as a longitudinal association with increased DeltaAA between visits. Particularly, relative to participants who never took any AHM, individuals with continuous AHM use had a higher DeltaAA of 0.6 year/chronological year. This finding underlines that DNAmAge and AA may not be able to capture the preventive effects of AHMs that reduce cardiovascular risks and mortality.},
	keywords = {Aged *Aging Antihypertensive Agents/classification/*therapeutic use DNA Methylation/*physiology Humans Hypertension/*drug therapy *DNA methylation age *antihypertensive medication *epigenetic epidemiology *hypertension},
	issn = {1945-4589 (Electronic) 1945-4589 (Linking)},
	doi = {10.18632/aging.101626},
	url = {https://www.ncbi.nlm.nih.gov/pubmed/30414594},
	author = {Gao, X. and Colicino, E. and J. Shen and Just, A. C. and Nwanaji-Enwerem, J. C. and C. Wang and Coull, B. and X. Lin and Vokonas, P. and Zheng, Y. and Hou, L. and Schwartz, J. and Baccarelli, A. A.}
}
